Loading the section…

IBRX: financial statements from SEC — TradeAlmanac

IBRX

ImmunityBio, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	44M	32M	26M	17M	6M	1M
Cost of revenue	238,000	177,000	136,000	58,000	0	0
Research and development	—	—	—	—	50M	51M
Selling, general and administrative	—	—	—	—	36M	49M
Operating expenses	114M	88M	98M	81M	86M	100M
Operating income	−70M	−56M	−71M	−64M	−80M	−99M
Pre-tax income	−633M	−67M	−92M	−130M	−86M	−135M
Income tax	9,000	−35,000	269,000	−234,000	0	0
Net income	−633M	−67M	−93M	−130M	−86M	−135M
Earnings per share	−0.62	−0.07	−0.10	−0.15	−0.12	−0.20
Earnings per share, diluted	−0.62	−0.07	−0.10	−0.15	−0.14	−0.20
Weighted average shares	1.03B	947M	888M	853M	696M	687M
Weighted average shares, diluted	1.03B	947M	888M	853M	698M	687M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	205M	88M	60M	138M	61M	143M	112M	130M
Short-term investments	176M	154M	198M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−75M	−86M
Depreciation and amortisation	4M	4M
Share-based compensation	8M	10M
Capital expenditure	2M	1M
Investing cash flow	−32M	4M
Financing cash flow	224M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator